LUNG CANCER HARB ORING HER2 MUTATION :EPIDE MIOLOGI CAL CHARACTE RISTICS AND, Q" Z# \+ [6 z0 B/ F- D. s) w3 q
THERAPE UTIC PERSPECTIVES; T- C3 i }, A7 v4 E: y& s
J. Mazieres, S. Peters
! h* r$ f, R7 \' U) _2 ^3 j9 KIntroduction: HER2 oncogene is a memb er of the EGFR family, encoding atransmembrane receptor that drives and regulates cell proliferation. HER2 mutations are identified in about 2% of non small cell lung cancer (NSCLC) , mainly located in exon 20, and appear to be critical for lung cancer carcinogenesis . Very scarce data are available to define a clinical profile of the patients harboring HER2 mutated NSCLC. We aimed to study clinic opatholog ical characteristics an d therapeutic
" p8 k% q& j& ], koutcomes of patients harboring HER2 mutation in a large European series. Result s:We retrospec tively ide ntified 46 NSCLC patients diagn osed with HER2 exon 20 mut ation. HER2 mutation was mainly exclusive as only one concomitan t KRas mutation was des cribed. Our population was characterized by a median age of 60 yr (31 to 86 yr), a high proportion of women (30 vs. 16 men, 65% ), and of never smokers (24, 52%). All tumors were adenoc arcinomas (two with lepidic features). Half of the patients had stage IV dise ase at the time of diagnosis. HER2 targeted" ]/ N8 j/ o0 `* L! v
treatment was delivered after convention al chemothe rapy. A total of 20 anti-Her2- k% I; K3 c. D
treatments were eval uable. We observed 4 progressive dise ases, 7 disease stabilizations
! I4 o" x9 @% O' I* f% q" G% Hand 9 partial resp onses according to RECIST 1.1 (overall response rate ORR = 45% ;( E" [/ Y" l }8 G/ |
disease control rate DCR = 80%). Specifica lly, we obse rved a DCR of 92% for/ W+ r' s8 C, _! G3 N
trastuzum ab-based therapie s (n = 14), 100 % for afatinib (n = 3) but no response to
! E c2 b8 J3 ~ D% u# g* z+ Blapatinib (n = 2) and to a multiTKI (n = 1). Median survival was of 68.2 months and
) ?' |( ^( }5 G22.9 months for respectively early stage and stag e IV patients.
* {( R2 K7 ~& V: K0 L1 C) rConclusion: This study, the largest to date dedic ated to HER2 mutated NSCLC,
x' l' w, E; L( breinforces the importance of an HER2 screening strategy in lung adenoc arcinomas .
' o9 l' H, r( H: j. o6 _! THER2-target ed drugs shou ld be tested further, ide ally withi n large collaborative
$ m1 x9 y6 P" Y. Mclinicaltrials.
1 [& Z, v4 d& | |